摘要
目的比较瑞舒伐他汀和阿托伐他汀对高胆固醇血症患者血浆脂蛋白相关性磷脂酶A2（LpPLA2）活性的影响。方法本试验为随机、双盲研究。在4周治疗性生活方式改善后，符合入选标准的高胆固醇血症患者随机分入瑞舒伐他汀5mg组（瑞舒伐他汀5mg／d）、瑞舒伐他汀10mg组（瑞舒伐他汀10mg／d）和阿托伐他汀10mg组（阿托伐他汀10mg／d），治疗8周。药物治疗前和治疗8周后测定血清总胆固醇、血清甘油三酯、血清低密度脂蛋白胆固醇、血清高密度脂蛋白胆固醇水平以及血浆Lp-PLA2活性。结果60例高胆固醇血症患者入选。治疗前各组血脂参数和血浆Lp-PLA2活性相似。治疗8周后，瑞舒伐他汀5mg组、瑞舒伐他汀10mg组和阿托伐他汀10mg组血清低密度脂蛋白胆固醇（LDL-C）水平分别降低35％、41％和36％，血浆Lp—PLA2活性降低幅度分别为15％、17％和15％。血浆Lp—PLA2活性和血清LDL-C水平相关（r=0．507，P=0．00）。结论高胆固醇血症患者瑞舒伐他汀和阿托伐他汀治疗8周后，血浆Lp-PLA2活性均显著下降。血浆Lp-PLA2活性和血清LDL-C水平相关。
Objective To evaluate the effect of rosuvastatin and atorvastatin on plasma lipoprotein-associat- ed phospholipase A2 （ Lp-PLA2 ） activity in patients with hypereholesterolemia. Methods This was a randomized, double-blind study, After a 4-week therapeutic lifestyle changes period, patients with hypercholesterolemia randomly received rosuvastatin （5mg/d} ,rosuvastatin （ 10 mg/d） and atorvastatin （ 10 mg/d） for 8 weeks. The levels of serurn total cholesterol, triglyceride,low-density lipoprotein cholesterol （ LDL-C ） ,high-density lipoprotein cholesterol and plasma Lp-PLA2 activity were measured at baseline and active treatment 8 weeks later. Results Sixty patients with hypereholesterolemia were enrolled in the study, Groups were matched, in accordance with the baseline characteristics. After statins therapy serum LDL-C decreaseti by 35% ,41% and 36% ;plasma Lp-PLA2 activity decreased by 15%, 17% and 15% in rosuvastatin （ 5mg/d ）, rosuvastatin （ 10mg/d ） and atorvastatin （ 10mg/d ）, respectively, The correlations between plasma Lp-PLA2 activity and the level of serum LDL-C （ r = 0.507, P = 0. 00 ） were observed. Conclusion The levels of plasma Lp-PLA2 activity are reduced significantly after rosuvastatin and atorvastatin therapy for 8 weeks in patients with hypereholesterolemia, There is correlation between plasma Lp-PLA2 activity and serum LDL-C.
出处
《中国综合临床》
北大核心
2008年第4期359-362,共4页
Clinical Medicine of China
